Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 integrase is a viral enzyme essential for the replication of Human Immunodeficiency Virus type 1 (HIV-1). It catalyzes the integration of viral DNA into the host cell genome, a critical step that allows HIV to establish persistent infection and evade immune responses. This makes integrase an attractive target for antiretroviral drug development. Integrase acts after reverse transcription has produced double-stranded viral DNA: 3'-Processing, Strand Transfer, Repair & Integration Completion. Integrase inhibitors are a major class of antiretroviral drugs used to treat HIV/AIDS by blocking this enzyme’s activity—thereby preventing establishment or propagation of infection within new cells.
Inhibition of integrase enzyme activity, preventing viral DNA integration into the host cell genome.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrase (Human Immunodeficiency Virus 1) (IN).